Valsartan Oral Liquid Composition Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current valsartan formulations, particularly for pediatric and geriatric patients, face challenges such as poor bioavailability, stability issues, and difficulty in administration due to poor solubility and solubilization in liquid forms, leading to inconsistent dosing and compliance problems.
Innovation Solution
Development of stable oral liquid compositions containing valsartan with cyclodextrin and/or cyclodextrin derivatives, alkali salts, and polyethylene glycol, which enhance solubility and stability, allowing for full solubilization and improved bioavailability, and are suitable for administration in a range of concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If valsartan is formulated as solid oral dosage forms (tablets, pills, capsules), then manufacturing and storage are simplified, but patient compliance deteriorates due to difficulty in swallowing especially for pediatric and geriatric populations
Solution Approach 1:
The patent transforms valsartan from a poorly water-soluble compound to a highly soluble liquid formulation by changing the physical state parameter from solid to liquid, and by adjusting the pH parameter to alkaline conditions (pH 7.0-9.0) where valsartan exhibits enhanced solubility. This allows the drug to be administered as an oral liquid that is easy to swallow while maintaining manufacturing feasibility through standardized formulation processes.
2Ease of operation
If valsartan is converted to oral liquid dosage forms, then patient compliance and ease of administration improve, but solubility and stability deteriorate leading to poor bioavailability and short shelf life
Solution Approach 1:
The patent achieves enhanced solubility by changing the pH parameter to alkaline conditions (pH 7.0-9.0) where valsartan's carboxylic acid group remains deprotonated, preventing precipitation. The formulation maintains this pH through the use of buffers and alkaline excipients, ensuring both solubility and stability throughout the shelf life.
Solution Approach 2:
The patent employs a composite formulation system combining valsartan with multiple excipients including buffers (phosphate, citrate, carbonate), surfactants (polysorbates, lecithin), and viscosity modifiers (carboxymethylcellulose, hydroxypropyl methylcellulose). This composite approach addresses solubility, stability, and bioavailability simultaneously, creating a synergistic formulation that overcomes the limitations of individual components.
3Adaptability or versatility
If extemporaneous compounding is used to prepare liquid valsartan formulations, then liquid dosage forms become available for patients, but dosing accuracy and consistency deteriorate due to lack of standardization
Solution Approach 1:
The patent provides pre-established, standardized formulation recipes with precise excipient ratios and preparation procedures. Pharmacists can directly dispense the pre-formulated liquid valsartan product without needing to perform extemporaneous compounding, thereby eliminating variability in dosing accuracy while maintaining the availability of liquid dosage forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oral liquid compositions provide improved bioavailability, stability, and ease of administration, ensuring consistent and precise delivery of valsartan, addressing the limitations of existing solid dosage forms and extemporaneously prepared formulations.
Implementation Method 1
liquid compositions containing active pharmaceutical ingredients that are completely solubilized in a liquid composition are more advantageous over suspension compositions
Implementation Method 2
an amount of at least one alkali salt sufficient to adjust the pH of the oral liquid composition to the range of about 5.5 to about 9.0
Implementation Method 3
Development of stable oral liquid compositions containing valsartan with cyclodextrin and/or cyclodextrin derivatives, alkali salts, and polyethylene glycol, which enhance solubility and stability
Data Source
AI summary
The present disclosure provides an oral liquid composition comprising valsartan with enhanced solubility and stability. Also, provided herein are methods of using the oral liquid compositions for the treatment of hypertension, treatment of heart failure and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.